三重阳性口腔状细胞癌患者预测生存结果不佳:多因素的阳性证明了修改治疗方法的需要
Priyansh Jain1, Mahesh Sultania2, Dillip Muduly1
1Department of Surgical Oncology, All India Institute of Medical Sciences, Bhubaneswar, Odisha India.
Journal of maxillofacial and oral surgery
|August 9, 2024
概括
淋巴血管侵袭 (LVI),围神经侵袭 (PNI) 和外节延伸 (ENE) 的存在显著影响口腔状细胞癌 (OSCC) 的存活率. 三重阳性OSCC患者经历了最糟糕的结果,强调了需要量身定制的治疗策略.
科学领域:
- 在瘤学瘤学.
- 口腔病理学 口腔病理学
- 手术瘤学手术瘤学
背景情况:
- 淋巴血管侵袭 (LVI),围神经侵袭 (PNI) 和外节延伸 (ENE) 是口腔状细胞癌 (OSCC) 的已知的预后指标.
- 这些不良病理特征对患者生存结果的综合影响需要进一步阐明.
研究的目的:
- 评估LVI,PNI和ENE对OSCC患者无病生存期 (DFS) 和整体生存期 (OS) 的单独和综合影响.
- 在OSCC中确定三重阳性 (LVI/PNI/ENE) 和双阳性疾病的预后意义.
主要方法:
- 对前性维护的口腔癌数据库的回顾性分析 (2017年1月 - 2023年3月).
- 包括连续的OSCC患者接受治疗性意图手术.
- 在生存分析中分类为三重阳性,双阳性和其他组.
主要成果:
- 在255名患者中,LVI,PNI和ENE阳性率分别为13%,26%和11%.
- 三重阳性疾病 (4%) 与非三重阳性组 (p<0.003) 相比,显著降低了DFS (0%vs. 57%) 和OS (0%vs. 72%).
- 双阳性疾病 (7%) 与单阳性/三阴性组相比,也显示出明显较差的DFS和OS (p<0.007).
结论:
- 三重阳性OSCC与极其糟糕的生存结果有关,没有观察到5年无病或整体生存.
- 多种不良因素 (LVI,PNI,ENE) 的存在需要对辅助疗法和整体治疗策略进行修改,以改善患者的生存率.
更多相关视频
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
9.6K
04:45Intraoperative Assessment of Resection Margins in Oral Cavity Cancer: This is the Way
Published on: May 10, 2021
3.7K
相关概念视频
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
